March 16, 2020 / 10:42 PM / 17 days ago

BRIEF-Cormedix Q4 Loss Per Share $0.21

March 16 (Reuters) - CorMedix Inc:

* . REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* QTRLY NET SALES $24.8 MILLION VERSUS $26.5 MILLION

* CORMEDIX - IN PROCESS OF SUBMITTING NDA FOR NEUTROLIN FOR PREVENTION OF CATHETER-RELATED BLOOD STREAM INFECTIONS VIA A ROLLING REVIEW GRANTED BY FDA

* BELIEVES IT HAS SUFFICIENT RESOURCES TO FUND OPERATIONS INTO Q2 OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below